Pavel I. Novikov

Pavel I. Novikov

Auto-generated profile, based on publicly available information

Pavel I. Novikov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2020 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
SMSergey V. Moiseev
Sergey V. Moiseev
JLJiwon M. Lee
Jiwon M. Lee
AZAnastasiia Zykova
Anastasiia Zykova
NBNikolay Bulanov
Nikolay Bulanov
PNPavel Novikov
Pavel Novikov
DJDavid R.W. Jayne
David R.W. Jayne

5 June 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
NCNatalia V. Chebotareva
Natalia V. Chebotareva
SGsergei Guliaev
sergei Guliaev
TAT. V. Androsova
T. V. Androsova
EPE. N. Popova
E. N. Popova
DGD. V. Gurova
D. V. Gurova
ГВГуляев Сергей Викторович
Гуляев Сергей Викторович
Recent studies have shown a high risk of chronic kidney disease and associated cardiovascular complications in patients with rheumatoid arthritis (RA), which determines the prognosis. However, the prevalence of chronic kidney disease (CKD) in RA has not been established in the Russians. Aim. Study was to examine the prevalence, risk factors and histological variants of CKD in RA. Materials and methods. 180 patients with rheumatoid arthritis were observed in the Tareev clinic of nephrology, for the period from 2014 to 2019 years. Age, gender, duration of RA, drug therapy, ESR, CRP, DAS28, renal function, proteinuria, histological variants were analyzed. Of the common population risk factors for CKD arterial hypertension, weight index, serum lipids and glucose levels were also assessed. Results. The prevalence of CKD in RA was 19.7%. Age, presence and stage of arterial hypertension, an increase in body mass index, as well as high rates of disease activity ESR, CRP, DAS28 score and duration of RA were risk factors of CKD in RA. Age, duration of the disease, stage of AH and hypercholesterolemia were risk factors in multifactorial regression analysis. Amyloidosis was the most common histologic pattern (50.0%), followed by chronic glomerulonephritis (30.4%) and tubulo-interstitial nephritis (19.6%). Among chronic glomerulonephritis mesangial glomerulonephritis was the most frequent. Renal amyloidosis was associated with a duration of RA, presence of systemic symptoms and CRP level. An isolated decrease in GFR of less than 60 ml/min was detected in 31 (36.0%) out of 86 patients. Сonclusion. The risk factors for CKD in patients with RA are activity and duration of the disease In addition to common population factors. Amyloidosis was the most common histologic pattern associated with duration of RA and inflammatory proteins levels.

17 June 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
NBNikolay Bulanov
Nikolay Bulanov
PNPavel I. Novikov
Pavel I. Novikov
MLMariia A. Litvinova
Mariia A. Litvinova
SMSergey V. Moiseev
Sergey V. Moiseev
Systemic vasculitis is a manifold group of systemic autoimmune diseases characterized by the inflammation of the blood vessels. The first clinical cases of systemic vasculitis were described in the Middle Ages, and most of the currently recognised nosological forms were reported in the first half of the 20th century. The first attempt to create a united classification of vasculitis was performed by P. Zeek in 1952. In the following decades accumulation of the data on the etiology and pathogenesis of different vasculitis guided researchers from different countries in their attempts to improve classification. The main principles of classification were the size of the affected blood vessels, disease etiology and pathogenesis. In 1990 American College of Rheumatology (ACR) published classification criteria for seven forms of the systemic vasculitis, that gave a significant contribution to the conduction of large-scale studies in this field. However, the first international nomenclature of vasculitis was developed only in 1994 during the Consensus Conference in Chapel Hill. Revised and augmented version of this nomenclature was created in 2012 and is still valid. An important step in the development of the classification of vasculitis was a joint project of ACR and EULAR aimed to develop new diagnostic and classification criteria for vasculitis (DCVAS). The first result of this project are the new classification criteria for granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis published in 2022. In general, the evolution of the classification of vasculitis occurs under the influence of the progress in the understanding of their etiology and pathogenesis.

1 June 2020 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
NBNikolay Bulanov
Nikolay Bulanov
ISIlya Smitienko
Ilya Smitienko
ASAnna Smagina
Anna Smagina
PNPavel Novikov
Pavel Novikov
SMSergey V. Moiseev
Sergey V. Moiseev

3 September 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AMAlexey D. Meshkov
Alexey D. Meshkov
AMAlexey L. Maslyansky
Alexey L. Maslyansky
NBNikolay Bulanov
Nikolay Bulanov
EFEkaterina E. Filatova
Ekaterina E. Filatova
PNPavel I. Novikov
Pavel I. Novikov
OTOlga N. Tkacheva
Olga N. Tkacheva
Glucocorticoids are the basis for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), however, their long-term use is associated with a number of well-known side effects. Despite the fact that a significant number of patients with these diseases require long-term treatment, approaches to long-term therapy remain insufficiently developed. The role of traditional anti-inflammatory drugs remains uncertain due to insufficient efficacy and inconclusive evidence base. A possible solution of this problem is the use of biological agents, in particular, affecting the interleukin (IL-6) axis. This series of clinical observations presents the experience of using the IL-6 inhibitor olokizumab in the treatment of GCA and PMR. The data obtained are consistent with the positive international experience of using drugs of this group and demonstrate both efficiency of disease activity control and a pronounced steroid-sparring effect. Olokizumab is a promising drug for the treatment of GCA and PMR.

1 January 2022 in Врач
Verified
Journal Article
Closed access
VOV. Oganov
V. Oganov
SMS. Mamykina
S. Mamykina
OZO. Zinovyeva
O. Zinovyeva
LSL. Strizhakov
L. Strizhakov
PNP. Novikov
P. Novikov
SMSergey V. Moiseev
Sergey V. Moiseev
Системные васкулиты (СВ) - группа заболеваний, объединенная наличием воспаления сосудистой стенки. Неврологические проявления могут возникать в дебюте СВ или на стадии полиорганного поражения. Диагностика поражений центральной и периферической нервной системы при АНЦА-ассоциированных васкулитах основана на данных неврологического осмотра и результатах лабораторных и инструментальных методов...